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Cyclin B knows its place
 
n mammalian cells the work of the cell cycle is divided 
between two workhorses: Cdk2/cyclin E for S phase and 
Cdk1/cyclin B for mitosis. Now, Jonathan Moore, Jane Kirk, 
and Tim Hunt (Cancer Research UK London Research Institute, 
London, UK) show that this apparent specificity is achieved 
by limiting access to substrates. By denying entrance to the 
nucleus, cells prevent Cdk1–cyclin B from jumpstarting S phase 
at inopportune times.
In frog egg extracts, S phase is 
induced in nuclei by Cdk2–cyclin 
E, but not by Cdk1–cyclin B. 
This difference has often been 
construed as specificity in cyclin 
substrate preferences, but the 
new results show that cyclin/Cdk 
pairs are in fact surprisingly 
promiscuous enzymes. Hunt’s group simply replaced the nuclear 
export signal from cyclin B with a nuclear localization signal and 
found that this altered Cdk1–cyclin B promoted both DNA 
replication and mitosis.
“I’m a biochemist,” says Hunt. “I tend to think in terms of 
specificity between substrate and enzyme. So it was a shock to 
find the different [CDKs] might not discriminate their substrates.” 
Vertebrate cells apparently avoid the danger that cyclin B might 
initiate S phase via its cytoplasmic localization and low levels 
during G
 
1
 
. In yeast, a single cyclin can, under some circumstances, 
promote both S phase and mitosis. Yeast may not have as severe a 
need to restrict cyclin activities because the G
 
2
 
 to M transition is 
less clear than in higher eukaryotes. “Maybe it’s okay to start 
mitosis early in yeast because chromosomes are still able to replicate 
as they are set on the metaphase plate,” Hunt suggests. 
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Though normally cytoplas-
mic (left), cyclin B (red) 
targeted to the nucleus 
(right) can start S phase.
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A cytokine that packs a punch
 
uscle cells undergo an unusual developmental 
program in which several partially differentiated cells 
called myoblasts fuse to form a multinucleated myotube. 
This nascent myotube undergoes further maturation and 
growth, which requires the addition of nuclei by fusion 
of more mononucleated myoblasts with myotubes. Valerie 
Horsley, Grace Pavlath, and colleagues (Emory University, 
Atlanta, Georgia) have found that nascent myotubes promote 
fusion, and thus their own growth, by secreting a cytokine 
normally associated with immune cells.
 The cross-system cytokine 
is IL-4, which is required in 
immune cells for macrophage 
fusion. Not one to throw 
away a good thing, Nature 
evidently coopted the system 
for muscle cells. As in 
immune cells, IL-4 expression 
in nascent myotubes is driven 
by a member of the NFAT 
transcription factor family. 
Myotubes lacking either IL-4 or the NFAT factor were 
smaller and had fewer nuclei than wild-type cells. Recovery 
from muscle injury was also diminished by the lack of IL-4 
or the IL4
 
 
 
 receptor.
Myoblasts are the targets of IL-4 action, which may 
promote fusion by inducing myoblast expression of adhesion 
molecules such as integrins (as in macrophages) or VCAM. 
Alternatively, IL-4 may act as a chemokine, as it does for 
osteoblasts, to stimulate migration of myoblasts toward 
myotubes. Whatever the mechanism, stem cell therapies 
for disorders such as muscular dystrophies may be improved 
by expression of IL-4 to increase the fusion capacity of the 
muscle stem cells. 
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Nascent myotubes (green) 
grow by IL-4–mediated fusion 
with myoblasts (red).
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Apoptosis leaves its mark on chromatin
 
NA gets condensed and chopped up 
during apoptosis. Despite these 
extensive changes, only one histone 
modification event—phosphorylation 
of histone H2B—has been specifically 
associated with apoptosis. Now, Wang 
Cheung, David Allis (University of 
Virginia, Charlottesville, VA), and 
colleagues provide evidence that this single 
change may be sufficient to induce the 
DNA changes during apoptosis.
Using a phosphospecific antibody, 
the authors identified the residue that is 
modified during apoptosis as a serine in the 
NH
 
2
 
-terminal tail of H2B. The antibody 
reacted with chromatin in dying cultured 
D
 
human cells and in clusters of cells under-
going apoptosis during tail resorption 
in developing frogs, indicating that the 
modification is well conserved.
The authors also 
show that the 
kinase responsible 
for H2B’s death 
stamp is Mst1, 
which is cleaved 
at the onset of 
apoptosis by 
caspase-3. Mst1 
phosphorylates 
H2B in vitro, 
and the cleaved 
form moves to the nucleus just before 
H2B phosphorylation in vivo. Expression 
of a truncated Mst1 induced H2B phos-
phorylation and DNA condensation and 
even led to cell death in the absence of 
proapoptotic insults. Although it is not 
clear how phosphorylation and conden-
sation are linked, the authors found that 
phosphorylated H2B tends to aggregate 
in denaturing conditions and thus may 
be intrinsically sticky. Alternatively, 
phosphate-modified H2B may recruit 
some as-yet-unidentified protein that 
condenses DNA.
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Phosphorylated 
H2B is found in 
condensed chroma-
tin in dying cells.
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